• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OptiNose Inc. (Amendment)

    1/30/24 4:05:56 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPTN alert in real time by email
    SC 13G/A 1 d717880dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    OPTINOSE, INC.

    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE

    (Title of Class of Securities)

    68404V100

    (CUSIP Number)

    DECEMBER 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 68404V100    SCHEDULE 13G    Page 1 of 9 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     AVISTA CAPITAL PARTNERS II GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     DELAWARE

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO


    CUSIP No. 68404V100    SCHEDULE 13G    Page 2 of 9 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     AVISTA CAPITAL PARTNERS II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     DELAWARE

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN


    CUSIP No. 68404V100    SCHEDULE 13G    Page 3 of 9 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     AVISTA CAPITAL PARTNERS (OFFSHORE) II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     BERMUDA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN


    CUSIP No. 68404V100    SCHEDULE 13G    Page 4 of 9 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     AVISTA CAPITAL PARTNERS (OFFSHORE) II-A, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     BERMUDA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN


    CUSIP No. 68404V100    SCHEDULE 13G    Page 5 of 9 Pages

     

    Item 1(a).

    Name of Issuer

    OptiNose, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices

    1020 Stony Hill Road, Suite 300

    Yardley, Pennsylvania 19067

     

    Item 2.

    (a) Name of Person Filing

    This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”:

    (i) Avista Capital Partners II GP, LLC

    (ii) Avista Capital Partners II, L.P.

    (iii) Avista Capital Partners (Offshore) II, L.P.

    (iv) Avista Capital Partners (Offshore) II-A, L.P.

    (b) Address of Principal Business Office or, if none, Residence

    All Reporting Persons:

    c/o Avista Capital Partners

    65 East 55th Street, 18th Floor

    New York, NY 10022

    (c) Citizenship

    Avista Capital Partners II GP, LLC and Avista Capital Partners II, L.P.: Delaware

    Avista Capital Partners (Offshore) II, L.P. and Avista Capital Partners (Offshore) II-A, L.P.: Bermuda

    (d) Title of Class of Securities

    Common Stock, par value $0.001 per share

    (e) CUSIP Number

    68404V100

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);


    CUSIP No. 68404V100    SCHEDULE 13G    Page 6 of 9 Pages

     

    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)    ☐    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

    The responses of the Reporting Persons to Rows (5) through (9), and (11) of the cover pages of this Amendment No. 4 are incorporated herein by reference.


    CUSIP No. 68404V100    SCHEDULE 13G    Page 7 of 9 Pages

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certifications

    Not Applicable


    CUSIP No. 68404V100    SCHEDULE 13G    Page 8 of 9 Pages

     

    EXHIBIT INDEX

     

    Exhibit

    No.

        
    A    Joint Filing Agreement, dated February 2, 2018 among Avista Capital Partners II GP, LLC, Avista Capital Partners II, L.P., Avista Capital Partners (Offshore) II, L.P. and Avista Capital Partners (Offshore) II-A, L.P. Incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on February 6, 2018 (Commission File No. 005-90169).


    CUSIP No. 68404V100    SCHEDULE 13G    Page 9 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

    Date: January 30, 2024

     

    AVISTA CAPITAL PARTNERS II GP, LLC
    By:   /s/ Ben Silbert
    Name:   Ben Silbert
    Title:   Authorized Representative
    AVISTA CAPITAL PARTNERS II, L.P.
    By:  

    Avista Capital Partners II GP, LLC

    its General Partner

    By:   /s/ Ben Silbert
    Name:   Ben Silbert
    Title:   Authorized Representative
    AVISTA CAPITAL PARTNERS (OFFSHORE) II, L.P.
    By:  

    Avista Capital Partners II GP, LLC

    its General Partner

    By:   /s/ Ben Silbert
    Name:   Ben Silbert
    Title:   Authorized Representative
    AVISTA CAPITAL PARTNERS (OFFSHORE) II-A, L.P.
    By:  

    Avista Capital Partners II GP, LLC

    its General Partner

    By:   /s/ Ben Silbert
    Name:   Ben Silbert
    Title:   Authorized Representative
    Get the next $OPTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPTN

    DatePrice TargetRatingAnalyst
    3/20/2025Buy → Hold
    Lake Street
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    3/11/2024$5.00Buy
    H.C. Wainwright
    8/21/2023$3.00Buy
    Lake Street
    10/21/2022$5.00Buy
    Jefferies
    More analyst ratings

    $OPTN
    SEC Filings

    View All

    SEC Form 15-12G filed by OptiNose Inc.

    15-12G - OptiNose, Inc. (0001494650) (Filer)

    6/2/25 1:57:42 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:04 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by OptiNose Inc.

    EFFECT - OptiNose, Inc. (0001494650) (Filer)

    5/22/25 12:15:09 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer & Corp Sec Marino Michael F Iii returned 125,204 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:54 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kohler Terry returned 30,541 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:25 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Fletcher R John

    4 - OptiNose, Inc. (0001494650) (Issuer)

    5/21/25 9:26:21 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first

    3/26/25 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptiNose downgraded by Lake Street

    Lake Street downgraded OptiNose from Buy to Hold

    3/20/25 8:56:55 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on OptiNose with a new price target

    H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously

    1/3/25 7:58:58 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on OptiNose with a new price target

    H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00

    3/11/24 7:44:36 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Financials

    Live finance-specific insights

    View All

    Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

    BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty

    5/21/25 8:26:34 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

    3/19/25 9:45:38 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

    Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w

    3/19/25 9:25:02 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Leadership Updates

    Live Leadership Updates

    View All

    Optinose Appoints Terry Kohler as Chief Financial Officer

    YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide

    10/7/24 4:59:53 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Announces CEO Transition and Business Update

    YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s

    1/31/23 7:00:00 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Optinose Appoints Paul Spence as Chief Commercial Officer

    YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,

    12/15/22 4:30:00 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/14/24 4:54:20 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptiNose Inc.

    SC 13G/A - OptiNose, Inc. (0001494650) (Subject)

    11/12/24 10:32:10 AM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care